Iclepertin for treating cognitive impairment associated with schizophrenia in people aged 18 to 80 years

Iclepertin is in clinical development for treating cognitive (thinking) impairment associated with schizophrenia (CIAS). Schizophrenia is a long-term mental health condition, which can be triggered by many different biological, social and psychological factors. The symptoms of schizophrenia are usually divided into positive symptoms (such as hallucinations and delusions), negative symptoms (such as emotional apathy, lack of drive, poverty of speech, social withdrawal, and self-neglect) and cognitive symptoms (such as working memory and executive function impairment). CIAS is a major burden for patients and negatively impacts many aspects of a patient’s life, and there are currently no approved pharmacological therapies for these cognitive impairments.